[Form 4] 10x Genomics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Serge Saxonov, who serves as Chief Executive Officer and a director of 10x Genomics, Inc. (TXG), reported a transaction on 08/22/2025 in which 9,348 shares of Class A common stock were sold at a price of $13.787 per share. The filing indicates the sale was made to cover tax withholding obligations related to the vesting of restricted stock units. After the reported transaction, the filing shows 945,892 shares held directly and additional indirect holdings reported as: 27, 89,825, 213,250, and 58,000 shares, each held via trusts for which the reporting person serves as trustee. The Form 4 was signed by an attorney-in-fact on 08/26/2025.

Positive

• Transparent disclosure of the insider sale and the reason: tax withholding for RSU vesting
• Substantial retained ownership: 945,892 shares reported directly after the sale and additional indirect trust holdings
• Indirect holdings documented with footnotes naming trusts and trustee role, aiding governance clarity

Negative

• Insider sale reported, though explicitly for tax withholding, it reduces the reporting person's direct share count by 9,348
• Limited context on whether other sales or planned transactions exist; the Form 4 covers only this specific disposition

Insights

Financial Analyst

TL;DR: Insider sold a small portion of holdings to cover RSU tax withholding; remaining direct and indirect holdings remain substantial.

The reported sale of 9,348 shares at $13.787 appears as a routine disposition to satisfy tax withholding from vested restricted stock units rather than a discretionary large-scale divestiture. The reported direct holding of 945,892 shares, together with multiple indirect trust holdings totaling material additional shares, means the reporting person continues to hold significant economic exposure to TXG. This filing does not provide information on broader trading patterns or scheduled plans; it documents a single, clearly explained transaction.

Corporate Governance Expert

TL;DR: Filing shows compliant disclosure and use of trusts for indirect ownership; sale is explicitly for tax withholding.

The Form 4 discloses both direct and indirect beneficial ownership and provides footnotes identifying the trusts that hold indirect shares, which supports transparency in insider ownership reporting. The disposition is labeled as covering tax withholding from RSU vesting, a common and accepted practice. The signature by an attorney-in-fact is noted, and the filing includes the necessary explanatory footnotes for the reported holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saxonov Serge

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CA 94588

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/22/2025		S(1)		9,348	D	$13.787	945,892	D
Class A Common Stock								27	I	See footnote(2)
Class A Common Stock								89,825	I	See footnote(3)
Class A Common Stock								213,250	I	See footnote(4)
Class A Common Stock								58,000	I	See footnote(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

2. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

3. The shares are held by the Sirius Trust, for which the Reporting Person serves as trustee.

4. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

5. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

	/s/ Eric S. Whitaker, as Attorney-in-Fact for Serge Saxonov	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Serge Saxonov sell according to the Form 4 for TXG?

The Form 4 reports sale of 9,348 shares of Class A common stock on 08/22/2025.

Why were the 9,348 shares sold in the TXG Form 4 filing?

The filing states the shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

At what price were the TXG shares sold in this reported transaction?

The shares were sold at a price of $13.787 per share.

How many TXG shares does Serge Saxonov beneficially own after the reported sale?

The Form 4 shows 945,892 shares held directly after the transaction, plus indirect holdings of 27, 89,825, 213,250, and 58,000 shares held via trusts.

Who signed the Form 4 for Serge Saxonov and when?

The Form 4 was signed by Eric S. Whitaker, as Attorney-in-Fact for Serge Saxonov on 08/26/2025.